Drugs / GSK1292263
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01101568 | Apr → Jun 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00783549 | Sep 2008 → Mar 2009 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01218204 | Sep 2010 → Jun 2011 | hyperlipidemia | GlaxoSmithKline | Completed | Mixed |
| Phase 2 | NCT01128621 | Nov 2009 → Apr 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT01119846 | Jun 2009 → Mar 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1292263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119846 ↗ |
| Known as | GSK-1292263A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3187503 ↗ |
| Known as | GSK-263A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3187503 ↗ |
| Known as | GSK263 | “We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-controlled studies that enrolled subjects with type 2 diabetes.” PMID 24699248 ↗ Apr 2014 |
| Action | Activate | “GSK1292263 (GSK263), a selective GPR119 agonist” PMID 24699248 ↗ Apr 2014 |
| Modality | Small molecule | — CHEMBL3187503 ↗ |
| Route | Oral | “Single Doses of Orally Administered Investigational Product” NCT00783549 ↗ |
| Target | GPR119 | “We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-controlled studies that enrolled subjects with type 2 diabetes.” PMID 24699248 ↗ Apr 2014 |